Antiplatelet therapy to prevent thrombosis after hip fracture. Rationale for a randomised trial.

Similar Items

• ANTIPLATELET THERAPY TO PREVENT THROMBOSIS AFTER HIP FRACTURE - REPLY
  by: Macmahon, S, et al.
  Published: (1995)
• The pulmonary embolism prevention (PEP) trial: Effects of low-dose aspirin on major vascular events in patients with hip fracture
  by: Prentice, C, et al.
  Published: (1999)
• Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement
  by: Kyung Won Kim, et al.
  Published: (2021-01-01)
• Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration.
  by: Collins, R, et al.
  Published: (1994)
• Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials.
  by: Yusuf, S, et al.
  Published: (1988)